TABLE II.
Survival rates and median overall survival by breast cancer subtype and known stage
| Subtype | Cases | Stage | Survival (% alive) at ... | Median overall survival | ||
|---|---|---|---|---|---|---|
|
|
|
|||||
| 1 Year | 5 Years | Months | 95% CI | |||
| TNBC | 3,277 | I | 98.8 | 93.3 | — | |
| II | 97.6 | 78.9 | — | |||
| III | 90.2 | 47.2 | — | |||
| IV | 41.1 | 7.4 | 8.9 | 6.7 to 11.1 | ||
|
| ||||||
| HER2+ | 4,902 | I | 99.6 | 96.5 | — | |
| II | 98.6 | 87.5 | — | |||
| III | 96.4 | 79.9 | — | |||
| IV | 74.6 | 36.6 | 37.3 | 28.0 to 43.0 | ||
|
| ||||||
| HR+ | 22,247 | I | 99.4 | 94.7 | — | |
| II | 98.7 | 88.1 | — | |||
| III | 96.0 | 72.9 | — | |||
| IV | 80.4 | 24.0 | 35.2 | 32.4 to 41.5 | ||
|
| ||||||
| All cases | 32,989 | I | 99.3 | 94.1 | — | |
| II | 98.3 | 86.3 | — | |||
| III | 95.0 | 70.8 | — | |||
| IV | 70.7 | 23.4 | 28.6 | 26.2 to 30.9 | ||
CI = confidence interval; TNBC = triple-negative breast cancer; HER2 = human epidermal growth factor receptor 2; HR = hormone receptor.